Abstract:

Tuberculosis is a serious public health problem and one of the top 10 causes of death worldwide. The treatment success rate is high in sensitive tuberculosis, and low in drug-resistant tuberculosis, while the mortality rate of drug-resistant tuberculosis is high. In recent years, the all-oral regimens with new anti-tuberculosis drugs as the core are greatly successful in treatment, overcoming the high incidence of adverse reactions of second-line injections, poor treatment compliance of patients and other shortcomings, and increasing the treatment success rate of drug-resistant tuberculosis. However, how to select anti-tuberculosis drugs for safe and effective oral regimens, and how to carry out researches on treatment program are still problems. In this paper, by reviewing the transition from chemotherapy drugs and injection-containing regimens to all-oral regimens for drug-resistant tuberculosis, as well as relevant studies on short and ultra-short course all-oral regimens at home and abroad and the basis for the formulation, the author made comments and shared thoughts and inspiration in combination with conditions in China, in order to provide reference for clinical researchers to better understand and carry out related researches.

Key words: Tuberculosis,pulmonary, Drug resistance, Administration,oral, Clinical protocols, Consensus development conferences as topic